Product Description
A bifunctional fusion protein composed of PD-1 mAb and IL-2c mutein (AWT020) is designed to enhance the therapeutic efficacy while reducing the IL-2 related toxicity. (Sourced from: https://jitc.bmj.com/content/10/Suppl_2/A1147)
Mechanisms of Action: PD-1 Inhibitor, IL2 Stimulant
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Anwita Biosciences
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Colorectal Cancer|Kidney Cancer|Melanoma|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Renal Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06839105 |
AWT020-001-I | P1 |
Recruiting |
Melanoma|Colorectal Cancer|Renal Cell Carcinoma|Non-Small-Cell Lung Cancer|Kidney Cancer |
2028-04-30 |
2025-06-03 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT06092580 |
AWT020-001 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-06-30 |
12% |
2025-09-03 |
Recent News Events
Date |
Type |
Title |
|---|